GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Price-to-Tangible-Book

Nuvectis Pharma (Nuvectis Pharma) Price-to-Tangible-Book : 11.63 (As of May. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Price-to-Tangible-Book?

As of today (2024-05-05), Nuvectis Pharma's share price is $8.14. Nuvectis Pharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.70. Hence, Nuvectis Pharma's Price to Tangible Book Ratio of today is 11.63.

The historical rank and industry rank for Nuvectis Pharma's Price-to-Tangible-Book or its related term are showing as below:

NVCT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.72   Med: 9.82   Max: 11.91
Current: 11.63

During the past 4 years, Nuvectis Pharma's highest Price to Tangible Book Ratio was 11.91. The lowest was 7.72. And the median was 9.82.

NVCT's Price-to-Tangible-Book is ranked worse than
90.43% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs NVCT: 11.63

A closely related ratio is called PB Ratio. As of today, Nuvectis Pharma's share price is $8.14. Nuvectis Pharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.70. Hence, Nuvectis Pharma's P/B Ratio of today is 11.63.


Nuvectis Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Nuvectis Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Price-to-Tangible-Book Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 7.72 11.91

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 16.96 13.52 13.37 11.91

Competitive Comparison of Nuvectis Pharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Nuvectis Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvectis Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Price-to-Tangible-Book falls into.



Nuvectis Pharma Price-to-Tangible-Book Calculation

Nuvectis Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=8.14/0.7
=11.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Nuvectis Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024

Nuvectis Pharma (Nuvectis Pharma) Headlines

From GuruFocus